Search

Displaying results 6141 - 6150 of 10000 in total
  1. Drug

    Rebamipide

    go.drugbank.com/drugs/DB11656
    ApprovedInvestigational

    Rebamipide has been investigated for the treatment of Stomach Ulcer, Keratoconjunctivitis Sicca, and Gastric Adenoma and Early Gastric Cancer.

    Categories: Compounds used in a research, industrial, or household setting
  2. Drug

    Zosuquidar

    go.drugbank.com/drugs/DB06191
    Investigational

    Zosuquidar is a compound of antineoplastic drug candidates currently under development. It is now in "Phase 3" of clinical tests in the United States.

  3. Drug

    Mebenil

    go.drugbank.com/drugs/DB14728
    Experimental

    An obsolete fungicide used to control various pathogens on cereals and seed potatoes.

  4. Drug

    Pegaptanib

    go.drugbank.com/drugs/DB04895
    ApprovedWithdrawn

    Pegaptanib is a polynucleotide aptamer. Pegatinib aids neovascular age-related macular degeneration by binding to VEGF which in order reduces angiogenesis and vessel permeability.

  5. Drug

    Tin protoporphyrin IX

    go.drugbank.com/drugs/DB16449
    Investigational

    Synonyms: Tin protoporphyrin IX, TIN, (DIHYDROGEN PROTOPORPHYRIN IX-ATO(2-))-
  6. Drug

    Vitespen

    go.drugbank.com/drugs/DB06400
    Investigational

  7. Drug

    CTB001

    go.drugbank.com/drugs/DB18316
    Investigational

    CTB001 is an anti-claudin 18.2 autologous chimeric antigen receptor (CAR) T-cell therapy under investigation for the treatment of gastric cancers.[L48146]

  8. Drug

    AL-034

    go.drugbank.com/drugs/DB17471
    Investigational

    AL-034 (TQ-A3334) is an oral toll-like receptor 7 agonist developed for the treatment of chronic hepatitis B (CHB) viral infection.

  9. Drug

    PF-03187207

    go.drugbank.com/drugs/DB05746
    Investigational

    Based on the very promising preclinical results and on the well-known activities of nitric oxide, PF-03187207 is expected to have an increased capacity to reduce high IOP. … The development of abnormally high IOP, due to blockage or malfunction of systems controlling the amount of fluid in the eye, is believed to be one of the principal causes of glaucoma.

  10. Drug

    ROX-888

    go.drugbank.com/drugs/DB05364
    Experimental

    ROX-888 is ROXRO's lead compound which is currently in Phase 3 trials for the treatment of acute pain, including post-operative pain.